Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298697 · ClinicalTrials.gov registry record · Phase 4
Biomarkers for Event-driven PrEP Adherence
A Phase 4 study of Human Immunodeficiency Virus, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT04298697 is a Phase 4 study of Human Immunodeficiency Virus that has completed, run by Emory University. The registered enrollment target is 43 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04298697, a Phase 4 study of Human Immunodeficiency Virus, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for the measurement of anti-retroviral drug concentrations in various body compartment sites. Participants will be involved in the study for up to 24 weeks.
Conditions Studied
Interventions
- DRUG Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Study Locations (1)
Georgia
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-02-28 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298697
The ClinicalTrials.gov registry entry for NCT04298697 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (77% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is the first listed.
NCT04298697 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04298697 about?
NCT04298697 is a clinical study titled "Biomarkers for Event-driven PrEP Adherence". This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for the measurement of anti-retroviral drug concentrations in various body compartment sites. Participants will...
What is the current status of trial NCT04298697?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2020-02-28. Estimated completion is 2022-08-09.
What conditions does trial NCT04298697 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT04298697?
The interventions under investigation include: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (DRUG).
Who is sponsoring clinical trial NCT04298697?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04298697 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.